The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K‐ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

• Published in: The oncologist (Dayton, Ohio) Vol. 14; no. 1; pp. 22 - 28
• Main Authors: Hurwitz, Herbert I., Yi, Jing, Ince, William, Novotny, William F., Rosen, Oliver
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01.01.2009
• Subjects: Adult; Aged; Aged, 80 and over; Angiogenesis inhibitors; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Disease-Free Survival; Female; Fluorouracil; Fluorouracil - administration & dosage; Genes, ras; Humans; Leucovorin - administration & dosage; Male; Middle Aged; Mutation; Predictive Value of Tests; Survival; Vascular endothelial growth factor

Purpose. Mutations of the K‐ras gene were identified as a prognostic marker in metastatic colorectal cancer (mCRC). In addition, emerging data suggest that K‐ras mutations are a negative predictor of clinical benefit from anti–epidermal growth factor receptor treatment in mCRC. Previously reported d...